Drugmaker Moderna has completed initial efficacy analysis of its Covid-19 vaccine from the drug's Phase 3 clinical study, and determined that it was 94.1% effective in preventing people from contracting Covid-19. This was reported by the press service of Moderna.
The new analysis from Moderna evaluated 196 confirmed Covid infections among the late-stage trial's 30,000 participants. The company said 185 cases of Covid were observed in the placebo group versus 11 cases observed in the group that received its vaccine. That resulted in an estimated vaccine efficacy of 94.1%, the company said.
Moderna also found that it was 100% effective in preventing severe cases (such as those that would require hospitalization) and says it hasn't found any significant safety concerns during the trial. On the basis of these results, the company will file an application for emergency use authorization (EUA) with the U.S. Food and Drug Administration (FDA) on Monday.
As we reported earlier, Russian developers of Sputnik V urged the British-Sweden pharmaceutical AstraZeneca Company to combine its vaccine-candidate with the Russian one to increase the efficacy of the drug.
“If they go for a new clinical trial, we suggest trying a regimen of combining the AZ shot with the #SputnikV human adenoviral vector shot to boost efficacy,” the developers of the Russian vaccine stated.